

This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

### Synthesis of Artificial Glycoconjugate Polymers Carrying 6-*O*-Phosphocholine $\alpha$ -D-Glucopyranoside, Biologically Active Segment of Main Cell Membrane Glycolipids of *Mycoplasma Fermentas*

Yoshihiro Nishida; Yusuke Takamori; Kazuhiro Matsuda; Hiroshi Ohru; Takeshi Yamada; Kazukiyo Kobayashi

**To cite this Article** Nishida, Yoshihiro , Takamori, Yusuke , Matsuda, Kazuhiro , Ohru, Hiroshi , Yamada, Takeshi and Kobayashi, Kazukiyo(1999) 'Synthesis of Artificial Glycoconjugate Polymers Carrying 6-*O*-Phosphocholine  $\alpha$ -D-Glucopyranoside, Biologically Active Segment of Main Cell Membrane Glycolipids of *Mycoplasma Fermentas*', *Journal of Carbohydrate Chemistry*, 18: 8, 985 – 997

**To link to this Article:** DOI: 10.1080/07328309908544048

**URL:** <http://dx.doi.org/10.1080/07328309908544048>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHESIS OF ARTIFICIAL GLYCOCONJUGATE POLYMERS  
CARRYING 6-O-PHOSPHOCHOLINE  $\alpha$ -D-GLUCOPYRANOSIDE,  
BIOLOGICALLY ACTIVE SEGMENT OF MAIN CELL MEMBRANE  
GLYCOLIPIDS OF *Mycoplasma fermentans***

Yoshihiro Nishida,\* Yusuke Takamori, Kazuhiro Matsuda,<sup>a</sup> Hiroshi Ohrui,<sup>b</sup>  
Takeshi Yamada and Kazukiyo Kobayashi\*

Department of Molecular Design and Engineering, Graduate School of Engineering,  
Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.

<sup>a</sup>Virology and Glycobiology Division, National Cancer Research Center Institute, Tsukiji  
5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

<sup>b</sup>Department of Applied Biological Chemistry, Faculty of Agriculture, Tohoku University,  
Tsutsumidohri-Amamiyamachi 1-1, Sendai 981, Japan.

*Received February 1, 1999 - Final Form June 23, 1999*

**ABSTRACT**

As carbohydrate probes to investigate the biological activity of novel phosphocholine-containing glycolipids of *M. fermentans*, artificial glycoconjugate polymers carrying 6-O-phosphocholine  $\alpha$ -D-glucopyranoside were synthesized. The synthesis involved  $\alpha$ -selective 1-O-p-nitrophenylation (*p*NP) of 1,6-di-O-acetyl-2,3,4-tri-O-benzyl-D-glucopyranose in the presence of a Lewis acid followed by the introduction of a phosphocholine group at position O-6 by an amidite method. The *p*NP group was converted into a *p*-N-methacrylamidophenyl group for subsequent radical polymerization.

## INTRODUCTION

Artificial glycoconjugate polymers carrying biologically active carbohydrates as the pendant groups represent a new class of biomimetic compounds.<sup>1</sup> They have been widely used in cell cultivations,<sup>2</sup> tumor diagnosis,<sup>3</sup> and detection and trapping of viruses and toxins.<sup>4,5</sup> The wide-range utility can be ascribed primarily to ubiquitous lectin-like receptors on germ and mammalian cell surfaces which recognize certain types of carbohydrate chains in glycopeptides and glycolipids. Moreover, multivalence and carbohydrate cluster effects in the protein-carbohydrate binding have contributed much to extend the potential utility of the artificial glycoconjugate polymers.<sup>6,7</sup> As a part of our research projects to develop such glycoconjugate polymers useful to investigate germ-host cell or toxin-host cell interactions,<sup>8-10</sup> our interest has been directed to novel phosphocholine-containing glycolipids, GGPL-I<sup>11,12</sup> and GGPL-III<sup>13-15</sup> (Figure 1). They are main cell membrane glycolipids of *M. fermentans* which is suspected of playing certain pathogenic roles in rheumatoid arthritis<sup>16</sup> and the progression of HIV diseases.<sup>17,18</sup> Biological activities of GGPLs have revealed a close relevance to those of *M. fermentans* itself. For example, they are determined to be species-specific major immunodeterminants<sup>19</sup> of *M. fermentans*, and their specific antibodies are widely detectable in the sera of HIV-1 infected individuals.<sup>20</sup> GGPL-III is suggested also to play a key role for the adherence of *M. fermentans* to Molt-3 lymphocytes.<sup>21</sup> These recent biological studies have inspired us to develop a convenient synthetic pathway to artificial glycoconjugate polymers carrying GGPL-I or GGPL-III analogues. In this article, we report a facile way to prepare the polymer carrying the GGPL-I analogue starting from D-glucose.

## RESULTS AND DISCUSSION

Potential biological activities of GGPLs are considered to be due to the phosphocholine group attached to the *O*-6 position of D-glucose.<sup>19,21</sup> This is mainly because human C-reactive protein, which increases in response to inflammation or tissue damage, has an ability to bind to phosphocholine-containing glycolipids leading to the activation of the complement system.<sup>22,23</sup> Moreover, it is also reported that all bacteria having a phosphocholine as the part of their surface structures show an activity to colonize a human nasopharynx.<sup>24,25</sup> Its existence at the position *O*-6 of  $\alpha$ -D-glucopyranose constructs a





Figure 1 Absolute Structures of GGPL-I and GGPL-III.

unique structure of GGPL-I different from phosphatidylcholine and the other phosphocholine-containing glycolipids.<sup>24,25,26</sup> Therefore, the skeleton of 6-*O*-phosphocholine  $\alpha$ -D-glucopyranose is considered to be the key functional group of GGPL-I for the biological activity. In this study, polymerizable GGPL-I analogues **10** (Scheme 2) carrying an *N*-methacrylamidophenyl group at the terminus were synthesized from D-glucose in a following manner.

We took a synthetic strategy starting from D-glucose *via* methyl  $\alpha$ -D-glucopyranoside **2** leading to 1,6-di-*O*-acetyl-2,3,4-tri-*O*-benzyl-D-glucopyranose **5** (Scheme 1). Though 1,6-anhydro-2,3,4-tri-*O*-benzyl- $\beta$ -D-glucopyranose **4** provides a conventional method to afford **5**,<sup>12</sup> acid catalyzed acetolysis for methyl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside **3** using 1% H<sub>2</sub>SO<sub>4</sub>/acetic anhydride (0°C to room temperature) gave **5** ( $\alpha/\beta=85/15$ ) directly in a high yield. The regioselective acetolysis at the primary *O*-benzyl group is considered to occur *via* a 1,6-anhydro intermediate **4**.<sup>27</sup> The di-*O*-acetylated derivative **5** was applied to *p*NP-glycosidation using *p*-nitrophenol (*p*NP-OH) and boron trifluoride-diethyl ether (BF<sub>3</sub>-Et<sub>2</sub>O) complex. After the reaction conditions were optimized by changing the solvent, reaction temperature and ratio of reagents as summarized in Table 1, *p*NP D-glucopyranoside **6** ( $\alpha/\beta=90/10$ , <sup>1</sup>H NMR analysis) was obtained in 93% yields using an excess amount of BF<sub>3</sub>-Et<sub>2</sub>O (6 mol equiv) and *p*NP-OH (4 mol equiv) in dichloromethane. Every reaction condition studied here showed high  $\alpha$ -selectivity probably due to the participation of the 6-*O*-acetyl group from the  $\beta$ -face.<sup>12,28,29</sup> Chromatographic separation of the desired *p*NP  $\alpha$ -glucoside **7** was performed



Scheme 1

Table 1. 1-*O*-*p*-Nitrophenylation of 1,6-Di-*O*-acetyl-2,3,4-tri-*O*-benzyl-D-glucopyranose.

entry	5 (α/β)	BF <sub>3</sub> ·OEt <sub>2</sub> equiv	<i>p</i> -nitrophenol equiv	solvents	conditions	yield <sup>a</sup> %	product (α/β) <sup>b</sup>
1	5 (85/15)	6	4	CH <sub>2</sub> Cl <sub>2</sub>	0 °C, 8.5h	93	6 (90/10)
2	5 (87/13)	4	4	CH <sub>2</sub> Cl <sub>2</sub>	0 °C, 16h	84	6 (89/11)
3	5 (81/19)	2	2	CH <sub>2</sub> Cl <sub>2</sub>	rt, 2h	69	6 (75/25)
4	5 (80/20)	4	4	toluene	0 °C, 6h	70	6 (87/23)
5	5 (87/13)	4	4	CH <sub>3</sub> CN	0 °C, 8.5h	35	6 (92/8)
6	5 (58/42)	4	4	CH <sub>3</sub> CN	0 °C, 6h	30	6 (>99/1)


a: Isolated yield after silica gel column chromatography.

b: Determined by <sup>1</sup>H NMR spectroscopy.

after de-*O*-acetylation with  $K_2CO_3$  in methanol. Here, the usual condition using sodium methoxide in methanol caused the partial decomposition of the *p*NP-glycoside linkage as well as the partial anomerization to some extents. A similar decomposition was observed upon the benzylation of a commercially available *p*NP  $\alpha$ -D-glucopyranoside using sodium hydride and benzyl bromide in DMF. This prompted us to undertake the present synthetic approach *via* methyl  $\alpha$ -D-glucopyranoside instead of using the *p*NP  $\alpha$ -D-glucopyranoside.

Introduction of a phosphocholine group at the position *O*-6 of **7** was attempted using phosphorous oxychloride and 2-bromoethanol according to our previous synthesis of GGPL-I.<sup>12</sup> The reaction gave the desired 6-*O*-phosphocholine derivative **8**, however, in poor yield (25%) because of the partial decomposition of the *p*NP-linkage at the stage converting the 2-bromoethyl group into choline. Therefore, a phosphorodiamidite method<sup>30</sup> was applied as an alternative approach (Scheme 2). Successive introduction of 2-cyanoethyl *N,N*-diisopropylphosphoramidite and then choline gave a product, which was oxidized *in situ* by a silver (II) dipicolinate.<sup>15,31-33</sup> After a usual process to remove the cyanoethyl group in aqueous ammonia in methanol followed by chromatographic purification (silica gel column), *p*NP 6-*O*-phosphocholine  $\alpha$ -D-glucopyranoside **8** was obtained in 54% yield. Catalytic hydrogenation using  $Pd(OH)_2$  in MeOH gave selectively a *p*-aminophenyl derivative **9a**, while the reaction in aq HCl-methanol afforded a debenzylated GGPL-I mimic **9b**. The primary amino group of **9a** and **9b** was converted into *N*-methacrylamido group using methacryloyl chloride in methanol to afford polymerizable GGPL-I analogues **10a** and **10b**, respectively.

Radical copolymerization of each of **10a** and **10b** with acrylamide (molar ratio: **10a**/acrylamide = 15/60; **10b**/acrylamide = 22/43) was carried out in an aqueous solution using ammonium peroxodisulfate (APS) and *N,N,N',N'*-tetramethylethylene diamine (TMEDA).<sup>34</sup> The acrylamide was selected to increase not only the water solubility but also the conformational flexibility of available polymers that are favored for multivalence interactions with possible GGPL-I binding proteins. The polymerization gave desired **Poly-10a** and **Poly-10b** as colorless powders after being precipitated in methanol and dialyzed (Mw. 3500 cut-off) in water. The <sup>1</sup>H NMR spectra showed that they contained each of the GGPL-I analogues in ca. 30% and 50% molar ratio, respectively, suggesting the sugar monomers might be more reactive than acrylamide under the reaction conditions employed here. The molecular weight was estimated to be ca.  $2 \times 10^6$  for both polymers by size exclusion chromatography.



In conclusion, we have presented a convenient synthetic approach towards artificial glycoconjugate polymers carrying GGPL-I analogues starting from D-glucose. The present approach will become a general way for the synthesis of the other glycoconjugate polymers carrying 6-*O*-phosphocholine glycosides as GGPLs analogues.

## EXPERIMENTAL

**General Methods.** Infrared (IR) spectra were recorded on a JASCO FT/IR-230 Fourier transform infrared spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were measured on Varian INOVA-500 (500 MHz, 125 MHz) or Varian Gemini 200 (200 MHz, 50 MHz) at ambient temperature. Chemical shifts are reported in parts per million. Tetramethylsilane and residual solvent peaks were used as internal references. Coupling constants are reported in Hertz (Hz). Optical rotations were measured on a JASCO DIP-1000 digital polarimeter. Size exclusion chromatography (SEC) was conducted with a JASCO 800 high-performance liquid chromatography on Shodex B804 + 805 columns at 40 °C using water as the eluent and calibrated with pulluran standards. For thin-layer chromatography (TLC) analysis throughout this work, Merck precoated TLC plates (silica gel 60 F<sub>254</sub>, layer thickness 0.25 mm) and Merck TLC aluminum roles (silica gel 60 F<sub>254</sub>, layer thickness 0.2 mm) were used. The products were purified by preparative column chromatography on silica gel (Merck Art. No. 7734, 70-230 mesh). Reactions sensitive to moisture or air were performed under nitrogen using anhydrous solvents and reagents. The following compounds, BF<sub>3</sub>-Et<sub>2</sub>O complex, *p*-nitrophenol, 1*H*-tetrazole, 2-cyanoethyl tetraisopropylphosphorodiamidite, and methacryloyl chloride are all commercially available. The experimental procedures for 1,6-anhydro 2,3,4-tri-*O*-benzyl- $\beta$ -D-glucopyranose **4** from D-glucose<sup>35</sup> and silver (II) bis (pyridine-2,6-dicarboxylate) monohydrate from silver nitrate and 2,6-pyridine dicarboxylic acid<sup>31-33</sup> were conducted as reported. Choline tosylate was prepared from choline chloride (*p*-toluene sulfonic acid (1 equiv), MeOH, rt, 2 h, crystallized in acetone (white crystal)).

### 1,6-Di-*O*-acetyl-2,3,4-tri-*O*-benzyl-D-glucopyranoside (**5**).

a) To a solution of trifluoroacetic acid (3.25 mL, 42.2 mmol) in acetic anhydride (65.0 mL, 688 mol) was added 1,6-anhydro 2,3,4-tri-*O*-benzyl- $\beta$ -D-glucopyranose **4** (6.49 g, 15.0 mmol) at room temperature. The reaction mixture was stirred for 6 h at the same temperature under dry condition (CaCl<sub>2</sub> tube). This solution was concentrated (azeotropy with ethanol and toluene). The residue was washed with water and saturated aq NaHCO<sub>3</sub> solution, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by silica gel column chromatography (AcOEt/CH<sub>2</sub>Cl<sub>2</sub>/*n*-hexane = 1/3/1 to 1/1/1 to 3/2/3) to give **5** (8.02 g, 15.0 mmol, 100%,  $\alpha/\beta=85/15$  (determined by 200 MHz  $^1\text{H}$  NMR)).



b) To a solution of methyl  $\alpha$ -D-glucopyranoside **2** (971 mg, 5.00 mmol) in 50 mL of DMF was added sodium hydride in oil, 60 % (1.20 g, 30 mmol, 6 equiv) at 0 °C. The solution was stirred for 0.5 h at the same temperature under dry conditions (CaCl<sub>2</sub> tube). To this was added benzyl bromide (3.51 mL, 30 mmol, 6 equiv) at 0 °C. The mixture was stirred for 1.5 h at 0 °C and then for 3.5 h at room temperature. The reaction was quenched by the addition of MeOH at 0 °C, filtered through a silica gel pad, and concentrated. The residual oil was washed with water and saturated aq NaCl solution, and extracted with CHCl<sub>3</sub>. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by silica gel column chromatography (AcOEt/*n*-hexane = 1/10 to 1/5 to 1/2) to give crude **3**. To the solution of crude **3** in 150 mL of Ac<sub>2</sub>O was added 10 mol % of H<sub>2</sub>SO<sub>4</sub> (26.7  $\mu$ L, 0.500 mmol) at 0 °C, and stirred for 3 h at room temperature. The reaction mixture was mixed with 100 mL of water, stirred for 1 h at 0 °C, washed with saturated aq NaHCO<sub>3</sub> solution, and extracted with CHCl<sub>3</sub>. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by silica gel column chromatography (AcOEt/*n*-hexane = 1/10 to 1/7 to 1/4 to 1/2 to 2/1) to give **5** (2.46 g, 4.61 mmol, 92 % (two steps),  $\alpha/\beta=76/24$  (determined by 200 MHz <sup>1</sup>H NMR)).

***p*-Nitrophenyl 6-*O*-Acetyl-2,3,4-tri-*O*-benzyl- $\alpha$ -D-glucopyranoside (**6**).**

To a solution of **5** (8.02 g, 15.0 mmol) in 250 mL of CH<sub>2</sub>Cl<sub>2</sub> was added boron trifluoride ether complex (11.1 mL, 90.0 mmol, 6 equiv) and *p*-nitrophenol (8.35 g, 60.0 mmol, 4 equiv) at 0 °C under nitrogen. The reaction was stirred at 0 °C for 8.5 h, quenched by the addition of water at 0 °C, washed with saturated aq NaHCO<sub>3</sub> solution, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel column chromatography (AcOEt/CH<sub>2</sub>Cl<sub>2</sub>/*n*-hexane = 1/4/15 to 1/4/10 to 1/4/7 to 1/4/5) to give **6** (8.58g, 14.0mmol, 93%,  $\alpha/\beta=90/10$  (determined by 200 MHz <sup>1</sup>H NMR )) as a pale yellow oil. Only the  $\alpha$ -anomer crystallized (white): mp 110-111 °C;  $[\alpha]_D^{23} +122.9^\circ$  (*c* 0.10, CHCl<sub>3</sub>); IR (KBr) 3072, 3030, 2894, 1727, 1590, 1517, 1494, 1454, 1346, 1234, 1111, 1066, 999, 874, 741, 700, 665, 455 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, rt, CDCl<sub>3</sub>)  $\delta$  8.21-8.18 (m, 2H, *o*-position of nitro group), 7.42-7.25 (m, 15H, C<sub>6</sub>H<sub>5</sub>), 7.13-7.11 (m, 2H, *m*-position of nitro group), 5.40 (d, *J*=3.5, 1H, H-1), 5.09-4.58 (m, 6H, CH<sub>2</sub>Ph), 4.25 (dd, *J*=12.5, 5.0, 1H, H-6), 4.20 (dd, *J*=10.0, 9.5, 1H, H-3), 4.14 (dd, *J* =13.0, 2.5, 1H, H-6), 3.83-3.80 (m, 1H, H-5), 3.73 (dd, *J*=9.5, 3.5, 1H, H-2), 3.60 (dd, *J* =9.5, 9.5, 1H, H-4), 1.97 (s, 3H, CH<sub>3</sub>CO); <sup>13</sup>C NMR (125 MHz, rt, CDCl<sub>3</sub>)  $\delta$  170.4, 161.2, 142.6, 138.3, 137.6, 137.4, 128.5, 128.5, 128.5, 128.4, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 125.7, 116.4, 95.3, 81.6, 79.5, 76.6, 75.9, 75.2, 73.7, 70.0, 62.3, 20.7.

Anal. Calcd for C<sub>35</sub>H<sub>35</sub>O<sub>9</sub>N: C, 68.50; H, 5.75; N, 2.28. Found: C, 68.39; H, 5.76; N, 2.20.

***p*-Nitrophenyl 2,3,4-Tri-*O*-benzyl- $\alpha$ -D-glucopyranoside (7).** To a solution of **6** (1.84 g, 3.00 mmol,  $\alpha/\beta=90/10$ ) in 100 mL of MeOH was added  $K_2CO_3$  (580 mg, 4.20 mmol) at room temperature. This solution was stirred for 2.5 h at the same temperature. The reaction mixture was neutralized with Amberlyst<sup>R</sup> 15E (1.50 g, rt, 1 h). This solution was filtered through a Celite pad and concentrated. The residue was purified by silica gel column chromatography (ether/*n*-hexane = 1/2 to 1/1 to 2/1 to 4/1) to give **7** (100%,  $\alpha/\beta=>99/1$  (determined by 200 MHz <sup>1</sup>H NMR), pale yellow oil).  $[\alpha]_D^{23} +131.5^\circ$  (*c* 0.10,  $CHCl_3$ ); IR (KBr) 3448, 3030, 2927, 1593, 1516, 1495, 1342, 1244, 1103, 1072, 1020, 872, 737, 696, 638  $cm^{-1}$ ; <sup>1</sup>H NMR (500 MHz, rt,  $CDCl_3$ )  $\delta$  8.20-8.18 (m, 2H, *o*-position of nitro group), 7.42-7.26 (m, 15H,  $C_6H_5$ ), 7.10-7.09 (m, 2H, *m*-position of nitro group), 5.40 (d, *J*=3.5, 1H, H-1), 5.07-4.63 (m, 6H,  $CH_2Ph$ ), 4.20 (dd, *J*=9.5, 9.5, 1H, H-4), 3.72-3.62 (m, 5H); <sup>13</sup>C NMR (125 MHz, rt,  $CDCl_3$ )  $\delta$  161.3, 142.5, 138.4, 137.6, 128.48, 128.5, 128.4, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 125.7, 116.3, 95.4, 81.4, 79.5, 76.3, 75.8, 75.1, 73.7, 72.2, 61.0.

Anal. Calcd for  $C_{33}H_{33}O_8N$ : C, 69.34; H, 5.82; N, 2.45. Found: C, 69.38; H, 5.78; N, 2.44.

***p*-Nitrophenyl 2,3,4-Tri-*O*-benzyl-6-*O*-phosphorylcholine- $\alpha$ -D-glucopyranoside (8).** To a solution of **7** (3.25 g, 5.69 mmol) and molecular sieves 4A (50 %w/w) in 100 mL of distilled  $CH_2Cl_2$  was added 2-cyanoethyl-*N,N,N',N'*-tetraisopropyl phosphorodiamidite (2.71 mL, 8.53 mmol, 1.5 equiv) and 1*H*-tetrazole (439 mg, 6.26 mmol, 1.1 equiv) at room temperature under nitrogen. The solution was stirred for 0.5 h at the same temperature. To this were added 1*H*-tetrazole (1.20 g, 17.1 mmol, 3 equiv) and then (after 3 minutes) choline tosylate (6.27 g, 22.8 mmol, 4 equiv) at room temperature. This solution was stirred for 4.5 h at room temperature, filtered through silica gel, and concentrated. The residue was diluted with  $MeCN/H_2O/MeOH = 4/1/1$  solution (120 mL). To this was added silver(II) bis(pyridine-2,6-dicarboxylate) monohydrate (7.79 g, 17.2 mmol, 3 equiv of **7**), and stirred for 1 h at room temperature. To the reaction mixture was added  $AcONa \cdot 3H_2O$  (3.10 g, 22.8 mmol, 4 equiv of **7**), and the mixture stirred for 0.5 h at room temperature. The solution was filtered through a pad of Celite and concentrated. The residual oil was diluted with 50 mL of MeOH, and to this was added 1 mL of 30 % aq  $NH_3$  and stirred for 1 h at room temperature. This solution was concentrated and purified by silica gel column chromatography ( $CHCl_3/MeOH/H_2O = 7/1/0$  to  $3/1/0$  to  $3/2/0$  to  $6/4/1$  to  $3/3/1$ ) to give **8** (2.20 g, 2.99 mmol, 53 % from **7**, white solid): mp 53-54 °C;  $[\alpha]_D^{25} +106.6^\circ$  (*c* 0.10,  $CHCl_3$ ); IR (KBr) 3406, 2935, 1593, 1518, 1495, 1344, 1246, 1090, 1024, 968, 739, 698, 461  $cm^{-1}$ ; <sup>1</sup>H NMR (500 MHz, rt,  $CDCl_3$ )  $\delta$  8.16-8.15 (m, 2H, *o*-position of nitro group), 7.35-7.22 (m, 15H,  $C_6H_5$ ), 7.15-7.14 (m, 2H, *m*-position of nitro group), 5.46 (d, *J*=3.0, 1H, H-1), 5.04-4.62 (m, 6H,  $CH_2Ph$ ), 4.19-4.05 (m, 4H, H-6 and  $POCH_2CH_2$ ), 3.90 (b, 1H, H-5), 3.76-3.70 (m, 2H, H-3 and H-4), 3.66 (dd, *J*=10.0,

3.0, 1H, H-2), 3.51 (b, 2H, CH<sub>2</sub>N), 3.09 (s, 9H, N(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, rt, CDCl<sub>3</sub>) δ 161.5, 142.3, 138.5, 138.3, 137.7, 128.4, 128.3, 128.3, 128.1, 127.9, 127.9, 127.6, 127.5, 125.7, 116.6, 95.4, 81.3, 79.2, 77.2, 75.5, 74.6, 73.4, 71.5, 71.5, 66.0, 63.5, 58.9, 53.9; MS for C<sub>38</sub>H<sub>45</sub>O<sub>11</sub>N<sub>2</sub>P 736.7596.

***p*-Aminophenyl 2,3,4-Tri-*O*-benzyl-6-*O*-phosphocholine- $\alpha$ -D-glucopyranoside (9a).** A mixture of **8** (970 mg, 1.32 mmol) and Pd(OH)<sub>2</sub>/C (200 mg) in 80 mL of MeOH was hydrogenated at room temperature under atmospheric pressure for 7 h. The reaction mixture was filtered through a pad of Celite and concentrated. The residue was purified by silica gel column chromatography (CHCl<sub>3</sub>/MeOH/H<sub>2</sub>O = 6/4/1 to 3/3/1 to 3/5/2) to give **9a** (853 mg, 1.21 mmol, 92 %, pale brown solid): mp 153-154 °C; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +74.5° (c 0.10, CHCl<sub>3</sub>); IR (KBr) 3403, 3031, 2923, 1635, 1510, 1454, 1361, 1224, 1087, 1028, 968, 921, 835, 737, 696, 532 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, rt, CDCl<sub>3</sub>) δ 7.35-7.21 (m, 15H, C<sub>6</sub>H<sub>5</sub>), 6.84 (d, *J* = 8.5, 2H, *m*-position of amino group), 6.59 (d, *J* = 8.5, 2H, *o*-position of amino group), 5.17 (d, *J* = 2.5, 1H, H-1), 5.02-4.56 (m, 6H, CH<sub>2</sub>Ph), 4.32 (broad s, 2H, NH<sub>2</sub>), 4.16-4.12 (m, 2H, H-6), 4.01-3.81 (m, 4H, H-3, H-5 and POCH<sub>2</sub>CH<sub>2</sub>), 3.60 (dd, *J* = 3.0, 9.8, 1H, H-2), 3.38 (b, 3H, H-4 and CH<sub>2</sub>N), 2.90 (s, 9H, N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, rt, CDCl<sub>3</sub>) δ 148.7, 143.5, 138.6, 138.1, 138.0, 128.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.8, 127.7, 127.5, 119.5, 115.6, 97.2, 81.6, 79.7, 78.2, 75.6, 74.9, 73.0, 71.3, 65.8, 65.0, 58.9, 53.8; MS for C<sub>38</sub>H<sub>47</sub>O<sub>9</sub>N<sub>2</sub>P 706.7756.

***p*-Aminophenyl 6-*O*-Phosphocholine- $\alpha$ -D-glucopyranoside (9b).** A mixture of **8** (765 mg, 1.04 mmol), Pd(OH)<sub>2</sub>/C (150 mg) and 35 %w/w aq HCl (10.4 mmol, 10 equiv) in 50 mL of MeOH was hydrogenated at room temperature under atmospheric pressure for 7.5 h. The reaction mixture was filtered through a pad of Celite and concentrated. The residue was purified by silica gel column chromatography (CHCl<sub>3</sub>/MeOH/H<sub>2</sub>O = 1/4/2 to 0/1/3 to 0/1/7) to give **9b** (441 mg, 1.01 mmol, 97 %, pale yellow solid): mp 199-200 °C; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +92.1° (c 0.10, H<sub>2</sub>O); IR (KBr) 3349, 2937, 2489, 1637, 1511, 1479, 1222, 1083, 968, 922, 833, 768, 478 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, rt, D<sub>2</sub>O) δ 6.85 (d, *J* = 8.5, 2H, *m*-position of amino group), 6.65 (d, *J* = 8.5, 2H, *o*-position of amino group), 5.26 (d, *J* = 4.0, 1H, H-1), 3.97 (b, 2H, POCH<sub>2</sub>CH<sub>2</sub>), 3.92-3.86 (m, 2H, H-6), 3.82 (b, 1H, H-5), 3.70 (dd, *J* = 9.5, 9.5, 1H, H-3), 3.53 (dd, *J* = 9.5, 4.0, 1H, H-2), 3.37 (dd, *J* = 9.5, 9.5, 1H, H-4), 3.33-3.31 (m, 2H, CH<sub>2</sub>N), 2.91 (s, 9H, N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR (125 MHz, rt, D<sub>2</sub>O) δ 149.3, 141.9, 119.4, 117.7, 98.7, 72.7, 71.3, 70.9, 69.0, 65.7, 64.3, 64.2, 59.2, 59.2, 53.7; MS for C<sub>17</sub>H<sub>29</sub>O<sub>9</sub>N<sub>2</sub>P 436.4024.

***p*-Methacryloylamidophenyl 2,3,4-Tri-*O*-benzyl-6-*O*-phosphorylcholine- $\alpha$ -D-glucopyranoside (10a).** To a solution of **9a** (754 mg, 1.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added methacryloyl chloride (0.210 mL, 2.13 mmol, 2 equiv) and triethylamine (1.49 mL, 10.7 mmol, 10 equiv) at room temperature. After the solution was stirred for 1 h, the mixture was extracted with CHCl<sub>3</sub>, processed as usual, and purified by

silica gel column ( $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O} = 3/2/0$  to  $1/1/0$  to  $6/4/1$  to  $3/3/1$  to  $2/5/3$ ) to give **10a** (761 mg, 0.983 mmol, 92 %, white solid): mp 129-130 °C;  $[\alpha]_{\text{D}}^{23} +55.1^\circ$  ( $c$  0.1,  $\text{CHCl}_3$ ); IR (KBr) 3392, 3031, 2925, 1664, 1626, 1509, 1454, 1409, 1361, 1223, 1086, 968, 835, 737, 698, 524  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz, rt,  $\text{CDCl}_3$ )  $\delta$  9.77 (b, 1H, CONH), 7.66 (d,  $J = 8.5$ , 2H, *o*-position of amido group), 7.39-7.25 (m, 15H,  $\text{C}_6\text{H}_5$ ), 6.98 (d,  $J = 9.0$ , 2H, *m*-position of amido group), 5.98 (s, 1H,  $\text{COCCH}_3\text{CHH}$ ), 5.35 (s, 1H,  $\text{COCCH}_3\text{CHH}$ ), 5.32 (d,  $J = 3.5$ , 1H, H-1), 5.05-4.57 (m, 6H,  $\text{CH}_2\text{Ph}$ ), 4.18 (m, 2H, H-6), 3.93-3.77 (m, 4H, H-3, H-5 and  $\text{POCH}_2\text{CH}_2$ ), 3.64 (dd,  $J = 3.0, 9.5$ , 1H, H-2), 3.37-3.33 (m, 3H, H-4 and  $\text{CH}_2\text{N}$ ), 2.93 (s, 9H,  $\text{N}^+(\text{CH}_3)_3$ ), 1.96 (s, 3H,  $\text{COCCH}_3$ );  $^{13}\text{C}$  NMR (125 MHz, rt,  $\text{CDCl}_3$ )  $\delta$  167.4, 152.8, 140.0, 138.4, 137.8, 137.7, 133.7, 128.9, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 127.7, 127.5, 122.6, 120.7, 117.1, 95.6, 81.5, 79.5, 78.2, 75.0, 73.2, 71.6, 65.7, 64.9, 58.7, 53.5, 18.9.

Anal. Calcd for  $\text{C}_{42}\text{H}_{51}\text{O}_{10}\text{N}_2\text{P}$ : C, 65.10; H, 6.63; N, 3.62. Found: C, 64.88; H, 6.76; N, 3.51.

**Acrylamide Copolymer (Poly-10a).** To a solution of **10a** (112 mg, 0.145 mmol) and acrylamide (32.8 mg, 0.580 mmol) in 2 mL of  $\text{H}_2\text{O}/\text{DMSO} = 3/1$  solution was added TMEDA (32.8  $\mu\text{L}$ , 0.218 mmol) and  $(\text{NH}_4)_2\text{S}_2\text{O}_8$  (0.1 g/mL water solution, 49.6  $\mu\text{L}$ , 21.8  $\mu\text{mol}$ ) at room temperature under nitrogen. This solution was stirred for 4 h at 50 °C and then for 3 h at 70 °C. To the reaction mixture was added MeOH, and the precipitate was collected by filtration to give **Poly-10a** (16.4 mg, 11 %, sugar/acrylamide = 33/67, white solid):  $^1\text{H}$  NMR (500 MHz, 50 °C,  $\text{DMSO}-d_6$ )  $\delta$  7.80-6.62 (b, aromatic proton), 5.76 (b, H-1), 5.18-4.41 (b,  $\text{CH}_2\text{Ph}$ ), 4.22-2.82 (b, H-2, H-3, H-4, H-5, H-6 and  $\text{POCH}_2\text{CH}_2\text{N}$ ), 2.60 (b,  $\text{N}^+\text{CH}_3$  and  $\text{CH}_3\text{CCO}$ ), 2.40-1.20 (b, main chain).

***p*-Methacryloylamidophenyl 6-*O*-Phosphorylcholine- $\alpha$ -*D*-glucopyranoside (10b).** To a solution of **9b** (101 mg, 0.232 mmol) in 5 mL of MeOH was added methacryloyl chloride (45.3  $\mu\text{L}$ , 0.464 mmol, 2 equiv) and triethylamine (0.323 mL, 2.32 mmol, 10 equiv) at room temperature. This solution was stirred for 1 h and concentrated to give a syrupy residue which was purified by silica gel column ( $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O} = 3/3/1$  to  $2/5/3$  to  $0/1/3$  to  $0/1/7$ ) to give **10b** (109 mg, 0.216 mmol, 93 %, yellow solid): mp 234-235 °C;  $[\alpha]_{\text{D}}^{25} +76.9^\circ$  ( $c$  0.19,  $\text{H}_2\text{O}$ ); IR (KBr) 3417, 2927, 1662, 1628, 1512, 1412, 1377, 1227, 1084, 1026, 964, 926, 872, 833, 768, 621, 521, 490  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz, rt,  $\text{D}_2\text{O}$ )  $\delta$  7.25 (d,  $J = 8.5$ , 2H, *m*-position of amido group), 7.03 (d,  $J = 8.5$ , 2H, *o*-position of amino group), 5.63 (d,  $J = 6.0$ , 1H, *cis*- $\text{C}(\text{CH}_3)\text{CHH}$ ), 5.45 (d,  $J = 4.0$ , 1H, H-1), 5.39 (d,  $J = 2.5$ , 1H, *trans*- $\text{C}(\text{CH}_3)\text{CHH}$ ), 3.95 (b, 2H,  $\text{POCH}_2\text{CH}_2$ ), 3.90 (m, 2H, H-6), 3.78 (b, 1H, H-5), 3.76 (dd,  $J = 9.5, 9.5$ , 1H, H-3), 3.58 (dd,  $J = 9.5, 4.0$ , 1H, H-2), 3.39 (dd,  $J = 9.5, 9.5$ , 1H, H-4), 3.33 (b, 2H,  $\text{CH}_2\text{N}$ ), 2.93 (s, 9H,  $\text{N}^+(\text{CH}_3)_3$ ), 1.83 (s, 3H,  $\text{CH}_3$ );  $^{13}\text{C}$  NMR (125 MHz, rt,  $\text{D}_2\text{O}$ )  $\delta$  170.7, 153.6, 139.4, 131.8, 124.5, 121.4, 118.0, 97.5, 72.7, 71.4, 70.9, 68.9, 65.7, 64.2, 59.2, 53.7, 17.6.

**Acrylamide Copolymer (Poly-10b).** To a solution of **10b** (109 mg, 0.216 mmol) and acrylamide (30.7 mg, 0.432 mmol) in water (2 mL) was added TMEDA (29.3  $\mu$ L, 0.194 mmol) and  $(\text{NH}_4)_2\text{S}_2\text{O}_8$  (1 g/L water solution, 1.48 mL, 6.48  $\mu$ mol) at room temperature under nitrogen. This solution was stirred for 10 h. To the reaction mixture was added MeOH, and the precipitate was collected by filtration to afford **Poly-10b** (76 mg, 54 %, sugar/acrylamide = 49/51, white solid): Decomposition point 260  $^\circ\text{C}$ ;  $[\alpha]_D^{27} +62.8^\circ$  (c 0.41,  $\text{H}_2\text{O}$ ); IR (KBr) 3398, 2939, 1670, 1512, 1481, 1412, 1227, 1084, 1026, 968, 926, 872, 833, 768, 606  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz, 50  $^\circ\text{C}$ ,  $\text{D}_2\text{O}$ )  $\delta$  7.55-7.04 (b, aromatic proton), 5.72 (b, H-1), 4.32 (b, H-6), 4.20 (b,  $\text{POCH}_2\text{CH}_2$ ), 4.05 (b, H-3 and H-5), 3.88 (b, H-2), 3.78-3.43 (b, H-4 and  $\text{CH}_2\text{N}$ ), 3.24 (b,  $\text{N}^+(\text{CH}_3)_3$ ), 3.17 (b,  $\text{CH}_3$ ), 2.59-1.20 (b, main chain);  $^{13}\text{C}$  NMR (125 MHz, 50  $^\circ\text{C}$ ,  $\text{D}_2\text{O}$ )  $\delta$  179.5, 150.8, 125.0, 124.9, 118.3, 118.2, 98.2, 73.1, 71.8, 71.3, 69.4, 66.2, 64.6, 59.6, 54.2, 42.2, 39.9, 39.6, 35.4.

## ACKNOWLEDGMENTS

This work is supported in part by Funding for the Regional Leading Research Project of Shizuoka Prefecture and by grants from the Ministry of Education, Science, and Culture, Japan (Priority Areas to K. K.). The authors are grateful also to Takeda Science Foundation and Tatematsu Foundation for financial supports to Y.N.

## REFERENCES AND NOTES

1. Y. C. Lee and R. T. Lee, in *Neoglycoconjugates: Preparation and Applications*, Academic Press: San Diego, 1994.
2. K. Kobayashi, A. Kobayashi, S. Tobe and T. Akaike, in *Carbohydrate-containing Polystyrenes in Neoglycoconjugates: Preparation and Applications*; Y. C. Lee and R. T. Lee, Ed.; Academic Press: San Diego, 1994, p 261.
3. N. V. Bovin and H. Gabius, *J. Chem. Soc. Rev.*, 413 (1995).
4. P. D. Rye and N. V. Bovin, *Glycobiology*, 7, 179 (1997).
5. P. D. Rye, *Biotechnology*, 14, 155 (1997).
6. Y. C. Lee, R. T. Lee and T. Rice, in *Enhanced Biochemical Affinities of Multivalent Neoglycoconjugates*; Y. C. Lee and R. T. Lee, Ed.; Academic Press: San Diego, 1994, p 23.
7. For recent papers see, a) E. G. Gordon, W. J. Sanders and L. L. Kiessling, *Nature*, 392, 30 (1998); b) S. K. Choi, M. Mammen and G. M. Whitesides, *J. Am. Chem. Soc.*, 119, 4103 (1997).
8. H. Uzawa, T. Toba, Y. Nishida, K. Kobayashi, N. Minoura and K. Hiratani, *Chem. Commun.*, 2311 (1998).
9. A. Tsuchida, K. Kobayashi, N. Matsubara, T. Suzuki and Y. Suzuki, *Glycobiology*, (1999) in press.
10. Y. Nishida, H. Dohi, H. Uzawa and K. Kobayashi, *Tetrahedron Lett.*, 39, 8681 (1998).

11. Isolation of GGPL-I, K. Matsuda, T. Kasama, I. Ishizuka, S. Handa, N. Yamamoto and T. Taki, *J. Biol. Chem.*, **269**, 33123 (1994).
12. Absolute configuration of GGPL-I, Y. Nishida, H. Ohruai, H. Meguro, M. Ishizawa, K. Matsuda, T. Taki, S. Hand and N. Yamamoto, *Tetrahedron Lett.*, **35**, 5465 (1994).
13. Isolation of GGPL-III, K. Matsuda, J.-L. Li, R. Harasawa and N. Yamamoto, *Biochem. Biophys. Res. Commun.*, **233**, 644 (1997) and *lit.* 14.
14. U. Zaehring, F. Wagner, E. T. Rietschel, G. Ben-Menachem, J. Deutsch and S. Rottem, *J. Biol. Chem.*, **272**, 26262 (1997).
15. Absolute configuration of GGPL-III, Y. Nishida, Y. Takamori, H. Ohruai, K. Matsuda, I. Ishizuka and K. Kobayashi, *Tetrahedron Lett.*, **40**, 2371 (1999).
16. M. H. Williams, J. Brostoff and I. M. Roitt, *Lancet*, **2**, 277 (1970).
17. K. Shibata and T. Watanabe, *FEMS Immun. Med. Microbiol.*, **17**, 103 (1997).
18. D. M. Phillips, P. R. Pearce, X. Tan and V. R. Zacharopoulos, *Aids Res. Hum. Retroviruses*, **8**, 1863 (1992).
19. K. Matsuda I. Ishizuka, T. Kasama, S. Handa and N. Yamamoto, *Biochim. Biophys. Acta.*, **1349**, 1 (1997).
20. J.-L. Li, K. Matsuda, M. Takagi and N. Yamamoto, *J. Immunol. Methods*, **208**, 103 (1997).
21. G. Ben-Menachem, F. Wagner, U. Zaehring, E. Th. Rietschel and S. Rottem, *FEMS Microbiol. Lett.*, **154**, 363 (1997).
22. G. Y. Kagan, Y. V. Volfovich, A. V. Zilfyan, I. V. Zheverzh and N. A. Gamova, *Zh. Mikrobiol. Epidemiol. Immunobiol.*, **3**, 107 (1982).
23. M. H. Kaplan and J. E. Volanakis, *J. Immunol.*, **112**, 283 (1974).
24. T. Behr, W. Fischer, J. Peter-Katalinic and H. Egg, *Eur. J. Biochem.*, **207**, 1063 (1992).
25. W. Fischer, T. Behr, R. Hartmann, J. Peter-Katalinic and H. Egg, *Eur. J. Biochem.*, **215**, 851 (1993).
26. M. Sugita, H. Fujii, F. Inagaki, M. Suzuki, C. Hayata and T. Hori, *Biol. Chem.*, **267**, 22595 (1992).
27. C. Wong, F. Moris-Varas, S. Hung, T. G. Marron, C. Lin, K. W. Gong and G. Weitz-Schmidt, *J. Am. Chem. Soc.*, **119**, 8152 (1997).
28. C. A. A. Van Boeckel, T. Beetz and S. F. van Aelst, *Tetrahedron*, **40**, 4097 (1984).
29. T. Fukase, T. Yoshimura, S. Kotani and S. Kusumoto, *Bull. Chem. Soc. Jpn.*, **67**, 473 (1994).
30. For recent applications for nucleic acid synthesis using an amidite method see: Y. Hayakawa and M. Kataoka, *J. Am. Chem. Soc.*, **119**, 11758 (1997), and the related references therein.
31. T. Noshita, T. Sugiyama, Y. Kitazumi and T. Oritani, *Tetrahedron Lett.*, **44**, 8259 (1994).
32. M. G. B. Drew, R. W. Matthews and R. A. Walton, *J. Chem. Soc., (A)*, 1405 (1970).
33. K. Kloc, J. Mlochowski and L. Syper, *Chem. Lett.*, **725** (1980).
34. R. Roy, F. D. Tropper and A. Romanoeska, *Bioconjugate Chem.*, **3**, 256 (1992).
35. I. Fujimaki, Y. Ichikawa and H. Kuzuhara, *Carbohydr. Res.*, **101**, 148 (1982).